ANNX Overview

Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is16.40 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Annexon Inc revenue for the last quarter amounts to -57.02M USD, increased 44.56

Annexon Inc. EPS for the last quarter amounts to -52352000.00 USD, increased 63.48

Annexon Inc (ANNX) has 100 emplpoyees as of March 11 2026.

Today ANNX has the market capitalization of 906.26M USD.